Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | CDC7 | O00311 | 2/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.36 |
| ▸ | CDK7 | P50613 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | PRKX | P51817 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675917 | 0.78 | NPY5R (0.43) | CDK2GSK3BCYP2D6AURKAMAPK8 | |
| SCHEMBL16682180 | 0.77 | CYP2D6 (0.51) | CDK2CYP2D6MAPK14PLK4NPY5R | |
| SCHEMBL16675967 | 0.73 | GSK3B (0.36) | CDK2GSK3BCDK1MAPK8DAPK3 | |
| SCHEMBL30142390 | 0.73 | FLT3 (0.42) | CDK2CYP2D6DYRK1AFLT3CSNK2A1 | |
| SCHEMBL16675943 | 0.72 | GRM4 (0.40) | GSK3BCYP2D6AURKARPS6KB1MAPK1 | |
| SCHEMBL16675948 | 0.71 | CYP2D6 (0.37) | CDK2GSK3BCDK1CYP2D6AURKA | |
| SCHEMBL16675940 | 0.71 | APOL1 (0.39) | CDK2GSK3BCDK1MAPK1 | |
| SCHEMBL16675911 | 0.70 | NPC1 (0.39) | CDK2CYP2D6AURKAMAP4K4RET | |
| SCHEMBL18556887 | 0.69 | CYP2D6 (0.48) | CDK2CYP2D6AURKARPS6KB1AURKB | |
| SCHEMBL16667690 | 0.69 | CLK2 (0.52) | CYP2D6AURKARPS6KB1MAP4K4CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CDK2 3048/4885GSK3B 4407/4885CDK1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.